Stifel Nicolaus analyst Benjamin Burnett maintained a Hold rating on Atara Biotherapeutics (ATRA – Research Report) yesterday and set a price ...

Atara Biotherapeutics Inc (ATRA) has disclosed a new risk, in the Corporate Activity and Growth category. Atara Biotherapeutics Inc faces ...

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr ...

TD Cowen analyst Phil Nadeau maintained a Buy rating on Atara Biotherapeutics (ATRA – Research Report) yesterday. The company’s shares closed ...

Atara Biotherapeutics is halving its headcount as it navigates the fallout from the FDA’s move to halt trials of the ...

Atara Biotherapeutics said it would lay off half of its workforce in a restructuring that came as the company narrowed its loss and logged higher revenue in the fourth quarter. The immunotherapy ...

Revenue: US$128.9m (up by US$120.4m from FY 2023). Net loss: US$85.4m (loss narrowed by 69% from FY 2023). US$11.41 loss per share (improved from US$65.18 loss in FY 2023). Revenue exceeded ...

Atara is working closely with its partners ... preserve resources Strategic review by financial advisor ongoing Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy ...

Full Year 2024 Results Key Financial Results Revenue: US$128.9m (up by ...

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to ...